Reimbursed Care Access in Trinidad and Tobago

Currently classified as a controlled psychotropic substance under the Dangerous Drugs Act of Trinidad and Tobago (listed in the Second Schedule alongside other UN psychotropic substances), with no authorised medical use or reimbursement outside approved clinical research. Possession, cultivation, distribution or manufacture without licence is an offence under the Act. #

Currently classified as a dangerous drug under amendments to the Dangerous Drugs Act (2019 amendments explicitly reference MDMA/‘3,4‑methylenedioxy‑methamphetamine’ among listed substances) and there is no routine medical approval, reimbursement, or authorised clinical treatment program for MDMA‑assisted therapy outside tightly regulated research. Criminal penalties apply for unauthorised possession or distribution. #

Esketamine (brand: Spravato) does not appear on Trinidad and Tobago public reimbursement lists and there is no public national programme or published Ministry of Health listing indicating registration or subsidy for esketamine; therefore it is not an established, reimbursed treatment in the public system. Ketamine (racemic) is listed on the Ministry of Health Pharmaceutical/VEN list as an injectable anaesthetic and is used clinically for anaesthesia in public hospitals, but esketamine (the nasal, Janssen product) requires national regulatory registration and local commercial importation to be available — there is no public evidence of a registered/reimbursed esketamine product in Trinidad and Tobago as of current public sources. Private clinics could theoretically import or procure off‑label products only if regulatory import/registration requirements are met; such use would be at private expense and subject to local medicines regulation. # #

Ketamine (racemic) is an approved and listed pharmaceutical for use in clinical settings in Trinidad and Tobago (included on the Ministry of Health national pharmaceutical/ven list as an injectable anaesthetic) and is therefore available for licensed medical indications such as anaesthesia in public and private hospitals. #

Off‑label psychiatric use (for treatment‑resistant depression or suicidal crisis) is a clinical practice seen worldwide; in Trinidad and Tobago such off‑label uses would fall under standard prescribing discretion but are not supported by a formal, reimbursed public programme or national psychiatric esketamine protocol. Reimbursement: public national reimbursement/supply covers approved essential medicines lists (ketamine for anaesthesia), but there is no documented, nationally funded programme reimbursing ketamine as a psychiatric/psychotherapeutic intervention — any such therapy in private practice would commonly be paid out‑of‑pocket or via private insurance only if a private insurer’s policy covers off‑label psychiatric treatments. Regulatory oversight for ketamine supply and use remains subject to Dangerous Drugs Act controls when relevant quantities or diversion risk are concerned. # #

Currently classified as a controlled psychotropic substance under the Dangerous Drugs Act (DMT named in the Second Schedule), with no authorised medical use or reimbursement outside approved clinical research. Use in sacramental contexts (ayahuasca) is not covered by national exemptions and would encounter DMT scheduling. #

Currently classified as a strictly controlled substance under national drug scheduling laws with no authorised medical use outside approved clinical research. (5‑MeO‑DMT falls within the Act’s listed tryptamine class and related controls.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public authorised ibogaine treatment program or reimbursement pathway in Trinidad and Tobago. #

Because ayahuasca contains DMT (a listed psychotropic in the Dangerous Drugs Act), its active constituent is controlled and there is no legal, reimbursed access for ayahuasca ceremonial or medical use outside tightly regulated research or special licences. Independent retreats or ceremonial use would risk enforcement under existing scheduling. #

Mescaline is explicitly listed in the Dangerous Drugs Act Second Schedule and is a controlled substance; there is no authorised medical use, routine access, or reimbursement aside from approved clinical research. Possession or distribution without licence is prohibited. #

Substituted phenethylamines (including the 2C family) and other new psychoactive substances are controlled under the Dangerous Drugs Act and its 2019 amendments; 2C‑X compounds have no authorised medical use or reimbursement in Trinidad and Tobago and are treated as illicit controlled substances except within approved research. # #